• Loss of mitochondrial phosphoenolpyruvate (PEP) impairs insulin release in vivo.
Introduction
A foregone conclusion from the consensus model of beta-cell glucose sensing is that glucokinase (GK)-regulated OxPhos lowers ADP to control plasma membrane depolarization associated with insulin secretion. Pharmacological targeting of either glucose entry at the beginning (GK activators) or depolarization at the end (sulphonylureas) of this canonical pathway stimulate secretion, but have had incrementally diminished long term therapeutic success (De Ceuninck et al., 2013; ; Efanova et al., 1998; ; Erion et al., 2014; ; Iwakura et al., 2000) . Successful targeting of the intermediate steps in the canonical pathway by other approaches, including enhanced OxPhos, have also been of limited success with no agents currently approved for use in humans. The OxPhos-independent mitochondrial GTP (mtGTP)-dependent phosphoenolpyruvate (PEP) cycle is a metabolic signaling pathway important for nutrientstimulated insulin secretion that provides an opportunity as a therapeutic target ( Figure   1A ). This pathway begins with the entry of glucose-derived pyruvate into the TCA cycle (anaplerosis) via the mitochondrial enzyme pyruvate carboxylase (PC) to generate oxaloacetic acid (OAA). OAA exits from the TCA cycle (cataplerosis) as PEP following the action of mtGTP-dependent PCK2 (Alves et al., 2015; ; Jesinkey et al., 2019; ; Stark et al., 2009 ). The cycle is completed when the PEP is then enzymatically hydrolyzed back to pyruvate by pyruvate kinase (PK) in order to lower cytosolic ADP. PK-mediated ADP lowering first slows down OxPhos and then closes KATP channels to depolarize the plasma membrane (Lewandowski et al., 2019) . There are also, cell-permeable, small-molecule allosteric PK activators that lower the Km for PEP, increase the frequency of metabolic and electrical oscillations and stimulate insulin release. As a potential therapeutic strategy not predicted by the consensus model, we question whether accelerating the PEP cycle with intravenous or oral delivery of PK activators 1) works in vivo, 2) is dependent on PCK2, and 3) can enhance insulin secretion in preclinical rodent models and diabetic human islets.
Results/Discussion

Enhancing oxidative metabolism does not improve islet function
The final step of glycolysis generates pyruvate which, due to the restricted expression of lactate dehydrogenase (LDH) from beta-cells, only has two potential dispositions: entry into oxidative metabolism via pyruvate dehydrogenase (PDH), or entry into anaplerotic pathways via PC (Schuit et al., 2012) . PDH kinase (PDK) phosphorylates PDH to inhibit PDH activity. Inhibiting PDK with the cell permeable dichoroacetate (DCA) reduces phosphorylation of PDH and, in principle, provides an acute pharmacological way to increase the oxidation of glucose (Sharma et al., 2019) . Rather than improving glucosestimulated insulin secretion (GSIS) by activating PDH, we confirmed prior in vivo and in vitro reports (Akhmedov et al., 2012) that DCA reduces insulin secretion in rat islets and rat insulinoma cells (INS-1) (Figures S1A- S1C). Mice with knockout of both isoform 2 and 4 of PDK (PDKdKO) mice have increased glucose oxidation rates as well as improved glucose tolerance, but paradoxically at the same time reduced plasma insulin levels (Wu et al., 2018) . PDKdKO mice were utilized to evaluate specifically whether increasing the oxidative potential by reducing PDK activity had a similar effect to DCA in intact islets without the off-target effects of DCA (James et al., 2017; ; Jeoung et al., 2012) . Perifused islets from PDKdKO mice had normal first phase insulin secretion, but the mitochondriadependent second phase was significantly decreased (Figures S1D and S1E) . Together, these DCA and PDKdKO data suggest that activating glucose OxPhos through inhibition of PDK would not be an effective therapeutic strategy to improve islet function.
PCK2 -/mice have impaired beta-cell function in vivo
Compared to oxidative flux through PDH, anaplerosis through pyruvate carboxylase (PC) is more steeply correlated with insulin secretion (Alves et al., 2015; ; Cline et al., 2004; ; MacDonald and Chang, 1985b; ; Prentki et al., 2013) . In principle, pyruvate oxidation, the cornerstone of the consensus model, does not change the concentration of TCA intermediates because OAA is regenerated with each turn of the cycle. Anaplerosis expands the TCA metabolite pool size through net synthesis of OAA while cataplerosis counterbalances this metabolite excess by exporting metabolites to shrink the TCA pool size. The mechanistic importance of pyruvate anaplerosis has been biochemically linked to the cataplerosis of OAA for the net synthesis of PEP in the PEP cycle (Jesinkey et al., 2019; ; Stark et al., 2009 ) . Since beta-cells do not have cytosolic PEPCK (PCK1), non-glycolytic synthesis of PEP is dependent on the reaction of mtGTP with anaplerotic OAA via PCK2 ( Figure 1A ) (Jesinkey et al., 2019; ; MacDonald and Chang, 1985a; ; MacDonald et al., 1992; ; Stark et al., 2009) . The importance of mtGTP synthesis was demonstrated in vivo and in vitro (Jesinkey et al., 2019; , still the involvement of cataplerosis via PCK2 in beta-cell function has only been supported in insulinoma cells in vitro (Jesinkey et al., 2019; ; Stark et al., 2009) . Whole body PCK2 -/mice were generated and backcrossed onto the C57Bl6j background. Knockout was confirmed by tissue mRNA, as well as islet protein and enzyme activity (Figures S1F-S1H). At 8 weeks of age the male mice have similar body weights as well as fasting plasma glucagon levels (Figures S1I and S1J).
As a sign of disrupted glucose homeostasis, fasting plasma glucose was elevated even on a regular chow diet (Figure 1B) . PCK2 -/mice demonstrated glucose intolerance during an oral glucose tolerance test (OGTT) (Figures 1C and 1D ) that could be explained, at least in part, by lack of an insulin secretion response ( Figures  1E  and  1F ).
To assess islet function more directly a hyperglycemic clamp was performed in the PCK2 -/mice which required a higher glucose infusion rate (GIR) to maintain glycemia at 300 mg/dl ( Figures  1G  and  1H) . The PCK2 -/mice were deficient in first- and second-phase insulin secretion accounting for at least part of the increased GIR and consistent with an essential role of PCK2 in glucose sensing ( Figure  1I ).
Both the PEP cycle and PK activation depend on PCK2
Islet intrinsic effects on beta-cell function from PCK2 -/mice were assessed directly via islet perifusions. Islet insulin content was not significantly different from PCK2 -/compared to controls ( Figure  S1K ), but GSIS from PCK2 -/islets confirmed the in vivo findings of reduced secretion with first-and second-phase GSIS compared to littermate controls ( (Figures  2A  and  2B ). In the accompanying manuscript, acute application of the PK activator 10 μM TEPP46 (PKa) to INS1 832/13 cells as well as mouse and human islets amplified insulin release (Lewandowski et al., 2019) . Here, PKa only stimulated insulin secretion from the controls identifying a dependence on PCK2-generated-PEP for the PKa-mediated effect ( Figures  2C  and  2D ).
PCK2 is required for the anaplerotic and PKa-dependent insulin secretory response
The cell permeable methyl ester of succinate (SAME) is exclusively an anaplerotic substrate unlike glucose which supplies both oxidizing and anaplerotic pathways (Alves et al., 2015) . SAME metabolism in beta-cells potently stimulates insulin secretion in vitro and in vivo (MacDonald and Fahien, 1988; ; Malaisse-Lagae et al., 1994; ; Zawalich et al., 1993) . In control mouse islets, SAME-stimulated insulin release was further potentiated by the PK activator ( Figure  2E ) similar to that seen in human islets (Lewandowski et al., 2019) . Just as with glucose, SAME did not stimulate as much insulin release from PCK2 -/islets as controls and did not synergize with PK activation, an indication that anaplerosis is dependent upon PCK2 for the PK-dependent salutary response. Remarkably, despite poor GSIS, PCK2 -/islets held at 8 mM glucose, akin to second-phase secretion, displayed a similar cytosolic calcium duty cycle and oscillation frequency to control islets, though the amplitude levels were slightly but significantly decreased (Figures 2F-2I ).
Either these small changes were sufficient to impair secretion, or this is also evidence of an additional role for PCK2 distal to cytosolic calcium. The calcium response following an acute increase in glucose is more indicative of first-phase secretion and was also diminished in PCK2 -/relative to controls ( Figures  2J  and  2K ). The calcium response in mouse islets at low glucose is especially sensitive to anaplerotic amino acids, a response that is muted as the glucose concentration dominates the response at higher concentrations (Lewandowski et al., 2019) . Here, control islets had the expected strong calcium response to an acute increase in amino acids that was further enhanced by PKa (Figures 2L and 2M) . PCK2 -/islets did not respond either to amino acids or to PKa suggesting that both PK activation and anaplerosis require PCK2 to stimulate insulin secretion.
PK activation improves insulin secretion in rodent and human models of T2DM.
PK activation improved insulin secretion from insulinoma cells as well as mouse and rat islets and healthy human islets in a glucose-dependent manner (Lewandowski et al., 2019) To assess potential translatability as a beta-cell enhancer in disorders of glucose homeostasis, we interrogated whether PK activation might improve islet function in diabetes models. Insulin secretion was improved in a glucose-dependent manner from islets isolated from male rats fed a 3-week HFD and then acutely treated with a structurally distinct, cell permeable and orally bioavailable PK activator, AG519 (PKa2) ( Figure  3A ).
PKa2-treated, KCl-depolarized islets further amplified insulin secretion ( Figure S2A) indicative of the contribution of PK activation in KATP-independent mechanisms. To determine the durability of the PK activator response, a second set of rats were fed HFD for three weeks with or without concomitant twice daily oral PKa2. Islets were isolated after an overnight fast without any additional PK activator treatment (either in vivo or following islet isolation). Despite the absence of dosing for 16 hours, the chronically PKa2 treated islets displayed glucose-dependent amplification of insulin release ( Figure 3B ) similar to acute treatment without a change in islet insulin content ( Figure S2B) suggesting either residual PKa2-mediated activation or in vivo protection from HFDinduced metabolic dysfunction.
Although a HFD increases insulin resistance and causes dysglycemia, it does not precipitate diabetes in normal rats. Therefore, we used the Zucker rat which is deficient in the leptin receptor and develops diabetes on a HFD (ZDF) compared to lean controls (ZF) ( Figure S2C ). ZDF islets had lower islet insulin content compared to ZF controls ( Figure S2C ) and had markedly diminished second-phase insulin secretion during the glucose perifusion ( Figures  3C  and  3D ). Notably, acute treatment of diabetic ZDF islets with PKa improved both first- and second-phase insulin secretion ( Figure  3C and 3D).
As an in vitro model of diabetic dysglycemia, normal human islets incubated for 72-hours under glucolipotoxic (GLT) conditions (20 mM glucose + 1 mM 2:1 oleate:palmitate) had diminished GSIS compared to normal culture conditions ( Figure   3E ). Acute treatment of control human islets with PK activator augmented insulin secretion in a glucose-dependent manner as in Lewandowski et al. (Lewandowski et al., 2019) . Treatment of GLT-exposed islets with PKa improved glucose-dependent insulin secretion to the level of the untreated control islets. As a more direct assessment of the potential translatability of PK activation to humans with T2DM, PK improved GSIS islets from 4 different bona fide T2D donors ( Figures  3F-3I ). In all of these diabetes models, PK enzymatic activity in islet lysates was not deficient and was fully activatable by PK activator (Figures S2D-S2F) . As was seen in insulinoma cells (Lewandowski et al., 2019) , multiple chemically distinct PK activators amplified insulin release from human islets ( Figure S2G ), reducing the likelihood of a single off-target mechanism to explain the improvement in islet function. Taken together, these in vitro data in multiple diabetes models using two chemically distinct PK activators, suggest PK activation may be a targetable mechanism to improve islet function and potentially beta-cell health.
PK activation improves insulin secretion and health in vivo
The glucose-dependency of PK activation was assessed in vivo. Following an overnight fast, healthy male rats were given a primed, continuous infusion of vehicle or either PKa or PKa2 with target plasma concentration of ~10 μM (Figure S3A ). Neither fasting glucose or insulin were altered in response to the drug infusion ( Figure  4A ). Following 90 minutes of continuous drug exposure, glucose concentrations were gently ramped to a peak of 250 mg/dl by a variable glucose infusion over 70 minutes ( Figure  4A ). Both PK activators significantly improved insulin secretion once glucose was raised above 150 mg/dl ( Figures  4B  and  4C) . A linear regression of all the individual glucose and insulin samples from the rats showed a doubling of GSIS at all points above this threshold ( Figure  S3B ). Consistent with higher insulin secretion, glucose infusion rate (GINF) was higher in PK activator treated rats (Figure S3C) . HFD-fed rats were treated for three weeks with twice daily oral vehicle or PKa2 and then subjected to an overnight fast in the absence of further drug administration. A hyperglycemic ramp was performed over 50 minutes. Fasting and ramped plasma glucose concentrations were identical between both groups ( Figure  4D ). Glucose infusion rate (GINF) was not changed in HFD-fed rats that were treated for three weeks with twice daily oral vehicle or PKa2 (Figure S3E) . In contrast, prior PKa2 treatment nearly doubled fasting and stimulated insulin levels compared to controls (Figure 4E and 4F) and was independent of bodyweight and plasma glucagon ( Figures  S3D  and  S3F ). Similar to the islets from the three-week HFD fed rats (Figure 3B) , the improved function may be a consequence of improved islet health and/or residual PK activation in the absence of treatment for 24-hours. Taken together, PCK2-dependent activation of the PEP cycle via two chemically distinct orally available small molecules improved islet function in preclinical diabetes models, in diabetic human islets and up to three weeks in vivo.
Conclusions
PK activation by small molecules improves insulin secretion in normal and diabetes models from insulinomas, mouse, rat, and human islets in a glucose-dependent manner.
This glucose-dependency minimizes the risk of hypoglycemia similar to GLP1R agonists but distinct from the increased risk from GK activation or sulfonylurea receptor agonism.
A benefit of PK activation would not have been predicted by the consensus mechanism of beta-cell glucose sensing, where GK is proposed to determine the extent of OxPhos.
Instead, this PK-dependent glucose-sensing is mechanistically dependent on anaplerotic metabolism (e.g., pyruvate carboxylase, amino acids, or SAME) coupled to PK through PEP produced by the mitochondrial GTP-dependent enzyme PCK2. As shown in the companion manuscript (Lewandowski et al., 2019) , the PK catalyzed reaction harnesses the free energy of PEP hydrolysis to cause ADP privation of both the mitochondria and KATP channels to depolarize the plasma membrane. The PK activator AG348 has been demonstrated to be well tolerated in Phase 1 healthy volunteer studies (Yang et al, 2018) and a Phase 2 trial in patients with PK deficiency (Grace et al., 2019; ; Yang et al., 2019) .
Our work does not identify an underlying PK deficiency per se contributing to islet dysfunction in T2D and may even argue against it. Nevertheless, these data provide supporting preclinical data that PK activation or other mechanisms that accelerate the PEP cycle may be beneficial targets in diseases such as T2DM where glucose metabolism is aberrant. 
Figure legends
Materials and Methods
Experimental model and subject details
All animal studies were approved by the Yale University Institutional Animal Care and Use Committee and were performed in accordance with all regulatory standards. -1900h) . All strains were on a C57BL/6J background and male mice were studied at 8 to 9 weeks of age. All of the mice studied were fed on a regular chow diet (Harlan Teklad TD2018: 18% fat, 58% carbohydrate, and 24% protein). Study cohorts consisted of homozygous PCK2 -/mice and littermate male WT controls. Catheters were placed in the jugular vein 6-9 days before the experiments;; only mice that recovered more than 95% of their pre-operative body weight were studied.
PCK2 -/mouse
Heterozygous PCK2 knockout mice (denoted C57BL/6NTac-Pck2 tm1 (KOMP)Vlcg , project ID VG13655) were obtained from the University of California Davis Knockout Mouse Project repository. For these knockout mice the VelociGene targeting strategy was employed, which enables the rapid and high-throughput generation of custom gene mutations in mice according to method described previously (Dechiara et al., 2009; ; Valenzuela et al., 2003) . Heterozygous PCK2 knockout mice were further crossed with C57BL6J mice to create PCK2 knockout mice on a C57BL6J background. Offspring that inherited the targeted PCK2 allele were interbred as heterozygotes for production of experimental PCK2 +/+ and PCK2 −/− mice. PCK2 −/− mice behave normally and are viable and fertile.
Hyperglycemic- clamp studies
In hyperglycemic clamp studies, overnight-fasted, awake mice under gentle tail restraint were infused with 20% D- glucose at a variable rate to maintain hyperglycemia (240-260 mg/dl). Plasma glucose was measured using a Analox GL5 Analyzer (Analox Instruments Ltd., UK). Serum insulin was measured via Mouse Ultrasensitive ELISA (80-INSMSU-E01, ALPCO). Fasting serum glucose and insulin concentration were also measured using the same methods, respectively.
For acute PKa treatment and hyperglycemic clamp: One week prior to experimentation, chow-fed male SD rats (~300g) underwent surgical arterial and venous catheterization.
After recovering from surgery, rats were starved overnight and received an intravenous bolus of compound PKa (11mg/kg) or vehicle control followed by a continuous infusion with compound PKa 0.17umol/kg/min throughout the entire infusion study. At the point of 90 minutes, 20% dextrose was infused at a variable rate to reach hyperglycemia (240-260 mg/dl). Blood samples (50 μl) were taken every 15 min for measurement of glucose using a YSI glucose analyzer.
For chronic PKa treatment and hyperglycemic clamp: HFD-fed rats treated with PKa were overnight fasted to start the experiment and the PKa in peanut butter was given before the overnight fasting. Plasma samples were collected before the start of infusion (basal 0 minute) to measure glucose and insulin levels. Rates of infused 20% glucose was variably increased as shown to reach target hyperglycemia while collecting plasma samples at 15, 30, 45, 60, 75, 90 minutes.
Oral glucose tolerance test (OGTT)
Glucose tolerance tests were performed after an overnight fast. Mice were gavaged with 1 g/kg glucose, and blood was collected by tail bleed at 0, 15, 30, 45, 60, 90, and 120 min for plasma insulin and glucose measurements. Plasma glucose concentrations were measured using the glucose oxidase method on an Analox GL5 Analyzer (Analox Instruments Ltd., UK). Serum insulin was measured via Mouse Ultrasensitive ELISA (80-INSMSU-E01, ALPCO). Fasting serum glucose and insulin concentration were also measured using the same methods, respectively.
Islet isolation and GSIS
Pancreata were excised from anesthetized rodents (rats and mice) and islets were isolated by collagenase P digestion followed by centrifugation with Histopaque 1100 solution for density separation of pure islets and then hand-picked as previously described (Kibbey et al., 2014) . Islets were allowed to recover for 24-48 hours in RPMI with 10% FBS and antibiotics with either 5mM glucose (rats) or 11mM glucose (mice).
Approximately 50-80 islets were then layered between a slurry of acrylamide gel column beads (Bio-Gel P4G;; BioRad150-412) and perifusion buffer DMEM Sigma) supplemented with 24mM NaHCO3, 2.5 mM glucose, 10 mM HEPES, 2 mM glutamine and 0.2% fatty acid free BSA. The islets were perifused at 100 ul/min for a 1hr equilibration period using a Bio-Rep Perifusion Instrument (Miami, FL) that maintains precise temperature, gas (5% CO2/95% air) and flow control. After the stabilization period, the islets were perifused with 2.5 mM glucose for 10 minutes followed by stimulatory 16.7 mM glucose for 45 minutes followed by 30 mM KCl as indicated. During the perifusion, outflow was collected into a 96-well plate format and secreted insulin concentrations were measured by a high range rodent insulin ELISA assay kit (ALPCO) and normalized to islet DNA which was measured using the Quant-iT PicoGreen dsDNA Reagent (Life Technologies Corporation).
Timelapse Imaging
For measurements of cytosolic Ca 2+ , islets were pre-incubated in 2.5 µM FuraRed (Molecular Probes F3020) in islet media for 45 min at 37°C before they were placed in a 
